Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 27;15(6):e094825.
doi: 10.1136/bmjopen-2024-094825.

Randomised controlled trial to assess the impact of hospital-community pharmaceutical care on drug-related problems in oncology practice for at-risk outpatients treated with oral anticancer drugs-a French Society for Oncology Pharmacy (SFPO) study: DROP-SFPO study protocol

Florence Ranchon  1   2   3 , Laure Huot  4   5 , Christophe Bardin  2   6 , Isabelle Madelaine  2   7 , Jean Louis Cazin  2   8   9 , Bertrand Pourroy  2   10 , Patrick Tilleul  2   11   12 , François Lemare  2   13 , Catherine Rioufol  14   2   3
Affiliations

Randomised controlled trial to assess the impact of hospital-community pharmaceutical care on drug-related problems in oncology practice for at-risk outpatients treated with oral anticancer drugs-a French Society for Oncology Pharmacy (SFPO) study: DROP-SFPO study protocol

Florence Ranchon et al. BMJ Open. .

Abstract

Introduction: Drug-related problems (DRPs) associated with oral anticancer drugs are frequent and require a new healthcare organisation to manage them on an outpatient basis. The aim of this article is to present the study protocol of the Drug Related problems in Oncology Practice (DROP) randomised controlled trial (RCT), endorsed by the French Society for Oncology Pharmacy. The main objective of the DROP RCT is to measure the impact at 6 months of the DROP community/hospital pharmaceutical intervention programme, compared with usual treatment, on the mean number of DRP (ie, adverse effects, drug-drug interactions, medication errors) related to oral anticancer drugs in at-risk outpatients.

Methods and analysis: The DROP protocol is a prospective, multicentre controlled clinical trial, with individual randomisation, comparing in parallel and in open, two groups of outpatients treated with oral anticancer drugs. The interventional group benefits from the DROP multidisciplinary intervention on oral anticancer treatment. The control group receives usual care. The primary outcome of the DROP RCT is the number of DRP due to oral anticancer drugs, per patient, identified between the inclusion of the patient and 6 months after inclusion ETHICS AND DISSEMINATION: Approval to conduct this study was obtained for all participating centres from an Ethics Committee (Comité de Protection des Personnes Sud-Méditerranée V) in August 2018 in accordance with French law. The trial results will be disseminated at clinical conferences and published in peer-reviewed journals.

Trial registration number: ClinicalTrials.gov: NCT03257969, recruitment started in June 2019. The current protocol version is V.9, 13 December 2023.

Keywords: CHEMOTHERAPY; Drug Utilization; Randomized Controlled Trial.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1. DROP-SFPO programme. C, medical consultation; M, month; SFPO, French Society for Oncology Pharmacy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–11. doi: 10.1182/blood-2008-12-196543. - DOI - PubMed
    1. Ziller V, Kalder M, Albert U-S, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol. 2009;20:431–6. doi: 10.1093/annonc/mdn646. - DOI - PubMed
    1. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28:4120–8. doi: 10.1200/JCO.2009.25.9655. - DOI - PMC - PubMed
    1. Partridge AH, Archer L, Kornblith AB, et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol. 2010;28:2418–22. doi: 10.1200/JCO.2009.26.4671. - DOI - PMC - PubMed
    1. Watson CH, Fish LJ, Falkovic M, et al. Adherence to Oral Anticancer Therapeutics in the Gynecologic Oncology Population. Obstet Gynecol. 2020;136:1145–53. doi: 10.1097/AOG.0000000000004170. - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data